Core Scientific, Inc/tx Form 4 insider transactions

Core Scientific EVP and CFO James P. Nygaard Jr. was granted 120,074 restricted stock units as part of an annual equity award.

Chief Legal and Administrative Officer Todd DuChene was granted 138,547 restricted stock units as part of an annual award.

Core Scientific, Inc. officer Todd Duchene sold shares of common stock valued at approximately $230,000 through a pre-arranged trading plan.

Core Scientific, Inc. reports that executive Todd M. Duchene sold shares of common stock as part of a pre-arranged trading plan.

Todd Duchene, Chief Legal and Administrative Officer of Core Scientific, Inc., reported the sale of 9,900 shares of common stock for $20.8499 per share and 100 shares for $21.53 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Core Scientific, Inc. reports that Chief Legal and Administrative Officer Todd DuChene sold 10,000 shares of common stock for $19.7952 per share, executed under a pre-arranged trading plan.

Chief Legal and Administrative Officer Todd M. DuChene disposed of 16,741 shares of Core Scientific, Inc. to cover tax liabilities following the vesting of restricted stock units.

CEO Adam Taylor Sullivan had 87,355 shares withheld to cover tax liabilities upon the vesting of restricted stock units.

Core Scientific, Inc. officer Todd DuChene reported the sale of common stock through a pre-arranged trading plan.

Core Scientific, Inc. officer Todd Duchene sold 10,000 shares of common stock for approximately $1.65 million under a pre-arranged trading plan.

Core Scientific CEO Adam Sullivan reported transactions involving restricted stock units and tax withholdings on March 31, 2026.

Core Scientific's Chief Legal Officer, Todd DuChene, reported transactions involving common stock, including a PSU grant settlement and share sales under a pre-arranged trading plan.

Core Scientific's CFO, James P Nygaard Jr., filed an amended Form 4 to correct the number of shares withheld for tax obligations related to restricted stock unit vesting.

Core Scientific's CFO, James P Nygaard Jr., reported the withholding of shares for tax obligations and the acquisition of additional shares from distributions.

Core Scientific Director Jeffrey David Booth was granted 18,575 restricted stock units, vesting in February 2027.

Core Scientific director Jordan Levy was granted 18,575 restricted stock units, vesting in February 2027.

Core Scientific director Elizabeth Crain was granted 18,575 restricted stock units, vesting in February 2027.

Core Scientific director Yadin Rozov was granted 18,575 restricted stock units, vesting in February 2027.

Core Scientific director Eric Stanton Weiss was granted 18,575 restricted stock units, aligning his interests with long-term shareholder value.

Core Scientific's CEO, Adam Taylor Sullivan, filed an amended Form 4 to correct the number of shares withheld for tax obligations related to restricted stock unit vesting.

Core Scientific CEO Adam Taylor Sullivan disposed of 274,404 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Core Scientific CEO Adam Taylor Sullivan reported an increase in beneficial ownership through RSU vesting and an in-kind distribution, alongside a sale to cover tax obligations.

Core Scientific's Chief Legal and Administrative Officer, Todd DuChene, acquired 55,758 performance-based restricted stock units and disposed of 139,873 shares to cover tax obligations, resulting in a net decrease in his beneficial ownership.

Core Scientific director Yadin Rozov reported a charitable donation of 40,100 shares of common stock.

Core Scientific's Chief Legal and Administrative Officer, Todd M. DuChene, reported a charitable donation of 20,000 Tranche 1 Warrants.

Core Scientific Director Yadin Rozov purchased 30,000 Tranche 1 Warrants, signaling confidence in the company's future.

Core Scientific Director Eric Stanton Weiss purchased 5,000 shares of common stock at $21.50 per share, increasing his beneficial ownership to 226,687 shares.

CoreWeave Inc. urges Core Scientific stockholders to vote FOR its proposed all-stock acquisition, disagreeing with proxy advisor recommendations.

Core Scientific provides supplemental disclosures for its merger with CoreWeave to address shareholder lawsuits challenging proxy statement information.

CoreWeave, Inc. filed a Form 425 communication regarding its proposed acquisition of Core Scientific, Inc., directing investors to key SEC documents.